Related Experiment Video
Updated: Jul 18, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Lung cancer genetics and pharmacogenomics
1Harvard Medical School-Partners, Healthcare Center for Genetics and Genomics, Cambridge, MA, USA. vjoshi@partners.org
Cytogenetic and Genome Research
|November 25, 2006
Summary
Epidermal growth factor receptor (EGFR) targeted therapies show success in some non-small cell lung cancer patients. Research is ongoing to identify biomarkers predicting response to these EGFR therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Epidermal growth factor receptor (EGFR)-targeted therapies are effective in a subset of non-small cell lung cancer (NSCLC) patients.
- The precise mechanisms driving response to these therapies are not fully understood.
- Identifying predictive biomarkers is crucial for optimizing treatment strategies.
Purpose of the Study:
- To investigate the molecular mechanisms underlying response to EGFR-targeted therapies in NSCLC.
- To identify potential biomarkers, including gene mutations and copy number alterations, associated with treatment response.
- To guide the development of predictive biomarker panels for patient selection.
Main Methods:
- Analysis of somatic mutations in genes within the EGFR signal transduction pathway.
- Assessment of copy number alterations in genes of the EGFR family.
- Correlation of genetic findings with clinical response data.
Main Results:
- Somatic mutations in specific genes and copy number alterations in the EGFR family are implicated in treatment response.
- These genetic factors represent potential candidates for predicting therapeutic efficacy.
- Further research is needed to validate these findings.
Conclusions:
- Genetic alterations in the EGFR pathway play a role in response to EGFR-targeted therapies for NSCLC.
- Biomarker discovery is essential for personalizing NSCLC treatment.
- Future studies should focus on developing and validating robust biomarker combinations.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
02:59Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...